logo
Americans are still waiting on Trump's pledge of IVF treatment for all

Americans are still waiting on Trump's pledge of IVF treatment for all

CBS News01-08-2025
Washington — On the campaign trail, Donald Trump made a pledge: Under his leadership, in vitro fertilization would be covered for all women and couples seeking the treatment. "We are going to be paying for that treatment," he said in an interview in August 2024.
After taking office, President Trump signed an executive order directing his domestic policy council to make recommendations on IVF policy changes by May. But that deadline has come and gone, and the White House has said little about the issue. Advocates for better IVF coverage are wondering what the holdup is.
Mr. Trump, who has called himself the "father of IVF" and claimed to be a "leader on fertilization, IVF," told NBC News, during that 2024 interview, that IVF would be covered for everyone who needs it.
"Under the Trump administration, we are going to be paying for that treatment," Mr. Trump, then a candidate, said. He added, "We're going to be paying for that treatment, or we're gonna be mandating that the insurance company pay."
Mr. Trump's executive order, signed in February, fell short of his campaign pledge, stating that it would be administration policy "to ensure reliable access to IVF treatment, including by easing unnecessary statutory or regulatory burdens to make IVF treatment drastically more affordable."
He directed his assistant for the White House Domestic Policy Council to submit within 90 days "recommendations on protecting IVF access and aggressively reducing out-of-pocket and health plan costs for IVF treatment."
That deadline would have fallen on May 19. Asked for an update, the White House declined to comment.
Cristina Gonzales and her partner, who live in New York City, have been struggling with infertility for about three years. Gonzales, who makes campaign ads for Democrats, is a part of a support group for women over 40 going through IVF. The women represent diverse political and ideological backgrounds, including liberals and those who support Mr. Trump, alike. When then-candidate Trump said IVF would be covered, Gonzales said some in her group "believed completely and wholeheartedly" that he would make coverage free.
"They deserve that promise to be kept," Gonzales said.
"This struggle of IVF is nonpartisan," she said. "It affects everybody."
In February, a Washington Post interview with Trump supporter and fired federal worker Ryleigh Cooper went viral. She said she didn't want to vote for Mr. Trump, but he'd promised to make IVF free. After reading the fact sheet from Mr. Trump's February executive order, she told the Post she said, "'That's bullsh**.'"
IVF is a fertility treatment that has broad support; in 2023, over 95,000 babies were born as a result of IVF — about 2.6% of all births in the U.S. — according to the American Society for Reproductive Medicine.
An overwhelming majority of Americans — 86% — think IVF should be legal, according to a March 2024 CBS News/YouGov poll.
"Eighty-six percent of Americans support IVF. That is unheard of in almost any issue you could think of in modern times," said Danielle Melfi, CEO of infertility advocacy nonprofit RESOLVE.
According to an April 2024 Pew survey, 79% of Democrats and those who lean Democratic say access to IVF is a good thing, as do 63% of Republicans and those who lean Republican. Even among Americans who told Pew abortion should be illegal in most cases, 60% view IVF access positively.
And Mr. Trump has introduced other concepts, including a "baby bonus" for babies born in the U.S., to help boost the U.S. birth rate. The fertility rate in the U.S. dropped to an all-time low in 2024, with fewer than 1.6 children being born per woman, according to new federal data. The bonus is available to parents who open so-called Trump Accounts, which were introduced in the president's massive domestic policy bill that he signed into law last month.
Melfi is optimistic about the momentum the issue has picked up and has made recommendations to the White House, among them, to increase health insurance coverage of all fertility-related treatment, include fertility coverage for veterans and military families, and cover fertility care for all federal employees.
Out-of-pocket costs are the biggest barrier to undergoing IVF, Melfi said. Each cycle — and many couples undergo several cycles — costs between $12,000 and $25,000. Very few states require insurance companies to provide coverage for the treatment, so the vast majority of women and couples must pay out of pocket for IVF rounds.
"Each state looks a little bit different, which is why action at the federal level would be really meaningful," Melfi said of state laws governing insurance coverage of IVF.
IVF is one of multiple infertility treatments available, and is often the last — and most expensive — step women take to become pregnant.
In the process, a woman typically administers expensive shots to herself every day to stimulate the growth of multiple eggs at once and regularly goes to a fertility clinic for ultrasounds and blood work to monitor progress. The eggs are retrieved, fertilized outside of the body and ideally, they develop into healthy embryos that can be implanted immediately or frozen for later use.
Many find it to be an exhausting process — physically, emotionally and financially.
Leading up to her first round of IVF, Gonzales was anxious. What if she and her partner were to spend all this money only for the procedure to not result in pregnancy?
"I don't have enough money for this and I feel like there's a lot of pressure on my body — what if it doesn't perform?" she said.
For her, an unexpected year-end bonus had provided a way to pay. But otherwise, it might not have been possible.
"When you look at health insurance policies, almost none of them cover fertility," Gonzales said. "Even so-called progressive states."
Still, IVF provides no guarantees. Gonzales has undergone four rounds of IVF, none of which resulted in a baby, and now, she and her partner are pursuing other paths to parenthood. IVF has ultimately been successful for other women in her IVF support group, and she thinks every person should have the chance to pursue the procedure, regardless of their financial circumstances.
"I don't regret it, I would definitely do it all over again," she said.
Gonzales hopes the president follows through on his pledge to make sure IVF is covered for those who want and need it.
"It would be one of the smartest policies for them to actually make good on this promise," she said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Elon Musk's Favorability Rating Among Americans Has Tanked Since January
Elon Musk's Favorability Rating Among Americans Has Tanked Since January

Yahoo

time30 minutes ago

  • Yahoo

Elon Musk's Favorability Rating Among Americans Has Tanked Since January

Elon Musk finished dead last in favorability in a recent Gallup poll asking Americans to assess 14 world figures. What Happened: Musk's approval ratings have taken a nosedive following his contentious tenure at the White House and the ensuing fallout with President Donald Trump. Musk's actions have not only tarnished his personal image but have also triggered a substantial decline in Tesla's sales and revenues. The Gallup poll showed that 61% of 1,000 randomly chosen American adults held a negative view of Musk. This follows Musk's participation in the Department of Government Efficiency, his warnings about the difficulties under a Trump presidency, and his plans to revamp government agencies. Before starting his White House work, Musk was viewed slightly more negatively than positively (43% favorable, 47% unfavorable). In the July poll, Musk's favorable rating was 33% favorable, with 61% unfavorable — a 24-point downward swing. Also Read: Ex-Trump Lawyer Says Trump Could Set Sights on Musk's Billions: 'It Bothers Him That He Is the Richest Man' The poll also shows a sharp drop in approval ratings for several current and former Trump administration figures, including Secretary of State Marco Rubio and President Trump, signaling a turbulent run-up to next year's midterm elections. The Gallup poll, conducted from July 7 to 21, revealed that Pope Leo XIV holds a net favorability score of +46, significantly higher than Ukrainian President Volodymyr Zelenskyy (+18) and Sen. Bernie Sanders (I-Vt.) (+11). Pope Leo's 57% favorability rating aligns with the initial ratings of his predecessors, Pope Francis and Pope Benedict XVI. Simultaneously, French President Emmanuel Macron and Rep. Alexandria Ocasio-Cortez (D-N.Y.) received mixed reviews, with a large portion of respondents expressing neutrality. Conversely, personalities like Health and Human Services Secretary Robert F. Kennedy Jr. and Israeli Prime Minister Benjamin Netanyahu were viewed unfavorably. Why It Matters: The plummeting popularity of Musk, a key figure in the tech and automotive industries, could have far-reaching implications. His controversial actions and the resulting public sentiment could potentially influence consumer behavior and investor confidence, impacting not just Tesla but the broader electric vehicle market. The termination of the federal program involving Musk also raises questions about the future of public-private partnerships in the tech sector. Read Next Independent Voters' Approval Rating Of Donald Trump Plummets, Latest Poll Indicates Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? TESLA (TSLA): Free Stock Analysis Report This article Elon Musk's Favorability Rating Among Americans Has Tanked Since January originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.

Cigna (CI) Pullback a Buying Opportunity, Says TD Cowen with a Buy Rating
Cigna (CI) Pullback a Buying Opportunity, Says TD Cowen with a Buy Rating

Yahoo

time30 minutes ago

  • Yahoo

Cigna (CI) Pullback a Buying Opportunity, Says TD Cowen with a Buy Rating

The Cigna Group (NYSE:CI) is one of the best defensive stocks to invest in according to analysts. Cigna shares cracked over 10% on July 31 after the company reported its Q2 2025 quarterly results. Following the results, TD Cowen analyst Charles Rhyee reiterated a Buy rating on Cigna, maintaining a $387 price target. He believes the recent pullback in the shares was overdone and sees current levels as an attractive entry point. A health care professional consulting with patients in a state-of-the-art facility. While concerns around performance in the Health Insurance Exchange (HIX) segment weighed on sentiment, Rhyee expects the impact to be limited. He points to strength in other parts of the business, particularly Specialty and Care Services, as well as solid momentum in the company's Pharmacy Benefit Management (PBM) operations, which should help offset pressures. Rhyee also noted that management's Q3 guidance appears cautious, especially considering stepped-up investment in improving patient experience. Still, he remains confident in the company's earnings outlook, with robust EPS growth projections for 2025 and 2026 supporting his valuation. The Cigna Group (NYSE:CI) is a health services company that provides medical, pharmacy, behavioural health, dental, and supplemental insurance products. While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and 10 Most Oversold Semiconductor Stocks So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Wells Fargo Sticks with Overweight on UnitedHealth (UNH), Trims Target to $267
Wells Fargo Sticks with Overweight on UnitedHealth (UNH), Trims Target to $267

Yahoo

time30 minutes ago

  • Yahoo

Wells Fargo Sticks with Overweight on UnitedHealth (UNH), Trims Target to $267

UnitedHealth Group Inc. (NYSE:UNH) is one of the best defensive stocks to invest in according to analysts. At the time of writing this article, UnitedHealth ranks among the 10 biggest year-to-date decliners, which have lost over 50% among U.S.-listed stocks with a market capitalization exceeding $2 billion. The company, which was marred by government investigations, operational failures, and leadership changes, reported mixed Q2 2025 earnings results at the end of July. Those results have been unable to shore up the share price, as the long-term growth outlook is still murky. A close-up of a healthcare professional studying a computer screen with data while consulting with a patient. The company guided for 2025 adjusted EPS to be over $16, which was significantly below Bloomberg's consensus expectations of $20.4. Seeing the brighter side, Jeff Jonas, portfolio manager at Gabelli Funds, called the guidance highly conservative and believes that it will be easier for the company to beat such low expectations. However, the steep correction and valuation discount have attracted analysts' interest, with around two-thirds of them having a Buy or equivalent rating. One of the analysts who maintains an optimistic view is Wells Fargo's Stephen Baxter. On August 4, Baxter maintained an Overweight rating on UnitedHealth but lowered his price target to $267 from $306. The revision followed a recently held management meeting where he assessed the company's updated outlook. According to the analyst, UnitedHealth's management remains confident in the company's ability to meet its reset 2025 guidance. In his view, management is taking a cautious but disciplined approach in factoring in cost trends and margin recovery. Baxter views this conservatism positively, suggesting it reduces the risk of further downside revisions. UnitedHealth Group Inc. (NYSE:UNH) is a healthcare company that provides health insurance and healthcare solutions in the U.S. and globally under the UnitedHealthcare and Optum brands. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and 10 Most Oversold Semiconductor Stocks So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store